BiotechTube
Home/Agomab Therapeutics/Colin Bond
CB

Colin Bond

Non-Executive Director, Chairman of Audit Committee

Agomab Therapeutics

Therapeutic Areas

FibrosisImmunology & Inflammatory Diseases

Agomab Therapeutics Pipeline

DrugIndicationPhase
AGMB-447Idiopathic Pulmonary Fibrosis (IPF)Phase 1b
Ontunisertib (AGMB-129)Fibrosis (unspecified)Phase 1
AGMB-101Fibrosis (unspecified)Phase 1

Leadership Team at Agomab Therapeutics

TK
Tim Knotnerus
Chief Executive Officer
PW
Philippe Wiesel
Chief Medical Officer
AS
Andrea Sáez
Chief Development Officer
PK
Pierre Kemula
Chief Financial Officer
PV
Paul van der Horst
Chief Business Officer
EL
Ellen Lefever
General Counsel
DE
David Epstein
Chairman of the Board
AJ
Angelika Jahreis
Non-Executive Director
FV
Felice Verduyn-van Weegen
Non-Executive Director (EQT Life Sciences)
OH
Ohad Hammer
Non-Executive Director (Pontifax)
View full Agomab Therapeutics profile